Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.

All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.

In order to present at Psychedelic Science 2023, speakers must agree to two out-of-the-ordinary requests about content exclusivity and MAPS’ reputation.

The Church of Psilomethoxin claims it’s the victim of “psychedelic capitalism,” but almost everything it claims is wrong.

The Church of Psilomethoxin now admits that its claims about psilomethoxin are solely based on faith. But how strong are the religious convictions of the Church?

Psymposia’s investigation into the Church of Psilomethoxin (CoP) turns to the Church’s claims that it’s currently “scientifically impossible” to test for psilomethoxin. Psychedelic chemist David Nichols calls that claim “completely nonsensical and nonscientific.

This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.

The Multidisciplinary Association for Psychedelic Studies (MAPS) quietly replaced founder Rick Doblin as Executive Director with Kris Lotlikar.

Last Week Tonight joined a long and growing list of media outlets that have added fuel to the hype of psychedelic medicalization. By omitting the potential risks and actual harms associated with psychedelic-assisted therapy, this messaging increases the risk to the public by presenting unrealistic expectations about experimental treatments.

Fluence will no longer seek a trademark for the phrase “Psychedelic Harm Reduction and Integration.”

Psychologist Ralph Hood’s study of serpent handling and mysticism helped legitimize the study of psychedelics. So why doesn't he want them approved for medical use?

From cultural appropriation to “Shroom Boom,” psychedelic online marketing gaffes and misrepresentations are becoming more and more prevalent from major psychedelic organizations.

Open Letter to MAPS Canada, MAPS, and MAPS PBC on Data Privacy and Doxxing. We believe that an organization responsible for private data, in such close proximity to criminalized subcultures, must take matters of privacy and security seriously.

As proponents of psychedelics begin to grapple with legacies of abuse, it’s time to learn from victims themselves. Psymposia is co-producing an investigative podcast series, Power Trip, with New York Magazine.

As the psychedelic pharmaceutical industry increasingly prioritizes personal data extraction through mobile apps, wearables, and so-called “targeted” medicine, a recent data breach by former MAPS Canada Executive Director Mark Haden provides a warning about some of the possible consequences to the financial incentives of datafication.

DoubleBlind claims its recently-unveiled New York City billboard is a lot of things, except what it actually is: a giant advertisement.

While COMPASS has issued a response defending the validity of its patents, one of the co-inventors says the patent examiner’s opinion is probably “a valid one.”

The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.

News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent applications.